CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 338 enrolled
Drug / intervention
R-Blocks +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00114348
NCT00114348Phase 4Completed

ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia

Charite University, Berlin, Germany·interventional·Posted Jun 15, 2005·Updated Feb 4, 2013

In Brief

A Phase 4 clinical trial evaluating R-Blocks and Protocol II-Ida for Lymphoblastic Leukemia, Acute and Lymphoma, Non-Hodgkin. Completed, enrolled 338 participants across 1 site.

Detailed Summary

The protocol ALL-REZ BFM 2002 aims at the optimization of treatment for children with relapsed acute lymphoblastic leukemia. The primary objective of study ALL-REZ BFM 2002 is the randomized comparison of a lower dosed and less intensive, but continuous consolidation therapy with conventional therapy administered in treatment blocks. Outcome measures are the reduction of minimal residual disease (MRD), event-free and overall survival, and the toxicity associated with each treatment strategy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 15, 2005
Enrollment StartAug 1, 2003
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 21.0 years ago

Interventions

R-Blocksprocedure

Protocol II-Idaprocedure